Amylyx Pharmaceuticals, Inc. SEC filings AMLX
Amylyx Pharmaceuticals, Inc. has 440 filings in SEC EDGAR's recent list, going back to Nov 17, 2015. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 8, 2026 | Sep 1, 2026 |
| 8-K |
Current report
Material agreement
|
Aug 20, 2026 | Aug 19, 2026 |
| 8-K |
Current report
Other events
|
Aug 18, 2026 | Aug 18, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 18, 2026 | Aug 18, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 4, 2026 | Jun 4, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 24, 2026 | Mar 24, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 3, 2026 | Mar 3, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jan 8, 2026 | Jan 8, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2025 | Nov 6, 2025 |
| 8-K |
Current report
Material agreement
|
Sep 10, 2025 | Sep 9, 2025 |
| 8-K |
Current report
Other events
|
Aug 27, 2025 | Aug 27, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2025 | Aug 7, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 5, 2025 | Jun 5, 2025 |
| 8-K |
Current report
Results of operations
|
May 8, 2025 | May 8, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 4, 2025 | Mar 4, 2025 |
| 8-K |
Current report
Material agreement
|
Jan 10, 2025 | Jan 10, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 30, 2024 | Dec 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2024 | Nov 7, 2024 |
| 8-K |
Current report
Other events
|
Oct 17, 2024 | Oct 17, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2024 | Aug 8, 2024 |
| 8-K |
Current report
Acquisition or sale of assets
|
Jul 10, 2024 | Jul 9, 2024 |
| 8-K |
Current report
Material agreement
|
Jun 21, 2024 | Jun 21, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 6, 2024 | Jun 6, 2024 |
| 8-K |
Current report
Results of operations
|
May 9, 2024 | May 9, 2024 |
| 8-K |
Current report
Other events
|
Apr 10, 2024 | Apr 10, 2024 |
| 8-K |
Current report
Exit or restructuring costs, Regulation FD disclosure, Other events
|
Apr 4, 2024 | Apr 3, 2024 |
| 8-K |
Current report
Officer or director change
|
Mar 14, 2024 | Mar 14, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Mar 8, 2024 | Mar 8, 2024 |
| 8-K |
Current report
Results of operations
|
Feb 22, 2024 | Feb 22, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 7, 2023 | Dec 7, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2023 | Nov 9, 2023 |
| 8-K |
Current report
Other events
|
Oct 13, 2023 | Oct 13, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2023 | Aug 10, 2023 |
| 8-K |
Current report
Other events
|
Jul 26, 2023 | Jul 26, 2023 |
| 8-K |
Current report
Other events
|
Jun 23, 2023 | Jun 23, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 9, 2023 | Jun 8, 2023 |
| 8-K |
Current report
Results of operations
|
May 11, 2023 | May 11, 2023 |
| 8-K |
Current report
Officer or director change
|
Mar 21, 2023 | Mar 13, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 13, 2023 | Mar 13, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 14, 2023 | Feb 14, 2023 |
| 8-K |
Current report
Material agreement
|
Dec 6, 2022 | Dec 1, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2022 | Nov 10, 2022 |
| 8-K |
Current report
Officer or director change
|
Nov 2, 2022 | Nov 1, 2022 |
| 8-K |
Current report
Other events
|
Sep 30, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2022 | Aug 11, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2022 | Aug 11, 2022 |
| 8-K |
Current report
Other events
|
Jul 5, 2022 | Jul 5, 2022 |
| 8-K |
Current report
Other events
|
Jun 13, 2022 | Jun 13, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 9, 2022 | Jun 9, 2022 |
| 8-K |
Current report
Other events
|
Jun 3, 2022 | Jun 3, 2022 |
| 8-K |
Current report
Results of operations
|
May 12, 2022 | May 12, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 31, 2022 | Mar 30, 2022 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Jan 11, 2022 | Jan 11, 2022 |
Showing 56 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AMLX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1658551
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.